Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of four immunomodulatory/immunosuppressive medications used for treating severe autoimmune conditions. The combination includes: - **Hydroxychloroquine**: A disease-modifying anti-rheumatic drug (DMARD) that suppresses Toll-like receptor activation and modulates immune system activity - **Mycophenolate mofetil**: An immunosuppressant that inhibits purine synthesis in lymphocytes - **Prednisolone**: A corticosteroid with broad anti-inflammatory and immunosuppressive effects - **Tacrolimus**: A potent calcineurin inhibitor that prevents T-cell activation and proliferation This combination provides multi-pathway immunosuppression and may be used in severe autoimmune conditions or complex cases requiring significant immune system modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydroxychloroquine + mycophenolate mofetil + prednisolone + tacrolimus.